Anixa Biosciences, Inc.

ANIX | News | $3.09 1.31% 1.29% 59K

(0.0% 1d) (-11.9% 1m) (-35.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 98,570,382
http://www.anixa.com
Sec Filling | Patents | 8 employees

(US) Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

cancer immunotherapy car-t t-cell genetic diagnostics ceiling

add to watch list Paper trade email alert is off

Press-releases

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| 0.0% | O: -1.89% H: 0.0% C: 0.0%
business cancer

Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Published: 2024-03-14 (Crawled : 13:30) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -0.31% | O: -0.94% H: 1.9% C: -2.22%
presentation meeting

Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -2.46% | O: -1.23% H: 2.18% C: 0.62%
vaccine congress world presentation

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Published: 2024-02-12 (Crawled : 12:30) - prnewswire.com
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -29.71% | O: 0.0% H: 3.51% C: -1.11%
cancer car-t trial

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -27.63% | O: -0.23% H: 6.75% C: 1.6%
conference

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -34.64% | O: 0.0% H: 3.09% C: 1.03%
patent vaccine cancer technology

Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
Published: 2024-01-10 (Crawled : 14:00) - prnewswire.com
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -21.92% | O: -0.25% H: 11.85% C: 9.38%
conference

Anixa Biosciences to Present at Biotech Showcase 2024
Published: 2023-12-14 (Crawled : 12:30) - prnewswire.com
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -18.93% | O: 0.51% H: 1.6% C: -3.31%
biotech

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 23:00) - prnewswire.com
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -19.34% | O: 2.29% H: 5.63% C: -10.45%
vaccine breast positive cancer study

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 21:00) - prnewswire.com
ANIX | News | $3.09 1.31% 1.29% 59K

Health Technology

| -19.34% | O: 2.29% H: 5.63% C: -10.45%
conference vaccine breast positive cancer ongoing study

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-24-014154	4	2024-04-10	2024-04-09	Buy	P	15009	838037
0001493152-24-010060	4	2024-03-15	2024-03-15	Buy	P	10000	110000
0001493152-24-010028	4	2024-03-15	2024-03-15	Buy	P	30000	491925
0001493152-24-002531	4	2024-01-17	2024-01-12	Buy	A	25000	25000
0001493152-24-002530	4	2024-01-17	2024-01-12	Buy	A	25000	25000